Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) shares have retraced a considerable 26% in the last month, reversing a fair amount of their solid recent performance. The good news is that in the last year, the stock has shone bright like a diamond, gaining 164%.

Even after such a large drop in price, Monte Rosa Therapeutics may still be sending bullish signals at the moment with its price-to-sales (or "P/S") ratio of 7.8x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 11.3x and even P/S higher than 78x are not unusual. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's limited.

How Monte Rosa Therapeutics Has Been Performing

Recent times have been advantageous for Monte Rosa Therapeutics as its revenues have been rising faster than most other companies. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Monte Rosa Therapeutics.

Is There Any Revenue Growth Forecasted For Monte Rosa Therapeutics?

Monte Rosa Therapeutics' P/S ratio would be typical for a company that's only expected to deliver limited growth, and importantly, perform worse than the industry.

Retrospectively, the last year delivered an explosive gain to the company's top line. Although, its longer-term performance hasn't been anywhere near as strong with three-year revenue growth being relatively non-existent overall. Therefore, it's fair to say that revenue growth has been inconsistent recently for the company.

Shifting to the future, estimates from the seven analysts covering the company suggest revenue growth is heading into negative territory, declining 43% per year over the next three years. With the industry predicted to deliver 141% growth per annum, that's a disappointing outcome.

With this in consideration, we find it intriguing that Monte Rosa Therapeutics' P/S is closely matching its industry peers. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.

The Bottom Line On Monte Rosa Therapeutics' P/S

The southerly movements of Monte Rosa Therapeutics' shares means its P/S is now sitting at a pretty low level. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

With revenue forecasts that are inferior to the rest of the industry, it's no surprise that Monte Rosa Therapeutics' P/S is on the lower end of the spectrum. As other companies in the industry are forecasting revenue growth, Monte Rosa Therapeutics' poor outlook justifies its low P/S ratio. Unless there's material change, it's hard to envision a situation where the stock price will rise drastically.

Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.